Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lisata Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the 2025 BIO International Convention
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Announces Research License with Catalent
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the Investival Showcase USA
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
News headline image
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.